Online first articles
Articles not assigned to an issue 9 articles
-
-
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
Authors
- Wenjie Li
- Wei Wang
- Content type: Brief Report
- Published: 03 May 2024
-
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia
Authors (first, second and last of 9)
- Huifen Zhou
- Xiaoxia Wu
- Miao Miao
- Content type: Research
- Open Access
- Published: 25 April 2024
-
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects
Authors (first, second and last of 11)
- Bei Cao
- Tingting Ma
- Juan Li
- Content type: Research
- Published: 11 April 2024
-
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
Authors
- Fatemeh Safari
- Setareh Bararpour
- Fatemeh Omidi Chomachaei
- Content type: Research
- Published: 27 March 2024
-
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Authors (first, second and last of 6)
- Tomoki Hori
- Kazuhiro Yamamoto
- Ikuko Yano
- Content type: Research
- Open Access
- Published: 27 March 2024
-
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer
Authors (first, second and last of 13)
- Noboru Yamamoto
- Miyako Satouchi
- Makoto Nishio
- Content type: Research
- Open Access
- Published: 26 March 2024
-
Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients
Authors (first, second and last of 8)
- Kazuma Fujita
- Daiki Taguchi
- Masatomo Miura
- Content type: Research
- Open Access
- Published: 22 March 2024
-
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Authors (first, second and last of 10)
- Maxime Chénard-Poirier
- Aaron R. Hansen
- Manish R. Sharma
- Content type: Research
- Open Access
- Published: 14 March 2024
For authors
Submit manuscriptWorking on a manuscript?
Avoid the most common mistakes and prepare your manuscript for journal editors.
Learn more